Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Dec 29;15(12):e0244242.
doi: 10.1371/journal.pone.0244242. eCollection 2020.

Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study

Richard Muwonge  1 , Partha Basu  1 , Tarik Gheit  2 , Devasena Anantharaman  3 , Yogesh Verma  4 , Neerja Bhatla  5 , Smita Joshi  6 , Pulikottil O Esmy  7 , Usha Rani Reddy Poli  8 , Anand Shah  9 , Eric Zomawia  10 , Surendra S Shastri  11 , Sharmila Pimple  12 , Priya R Prabhu  3 , Sanjay Hingmire  13 , Aruna Chiwate  13 , Catherine Sauvaget  1 , Eric Lucas  1 , Sylla G Malvi  13 , Maqsood Siddiqi  14 , Subha Sankaran  3 , Thiraviam Pillai Rameshwari Ammal Kannan  3 , Rintu Varghese  3 , Uma Divate  6 , Shachi Vashist  5 , Gauravi Mishra  12 , Radhika Jadhav  6 , Massimo Tommasino  2 , M Radhakrishna Pillai  3 , Rengaswamy Sankaranarayanan  15 , Kasturi Jayant  15 ; Indian HPV vaccine study group
Affiliations
Multicenter Study

Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort study

Richard Muwonge et al. PLoS One. .

Abstract

In context of the ongoing multi-centric HPV vaccine study in India, unvaccinated married women (N = 1484) aged 18-23 years were recruited in 2012-2015 as age-matched controls to the vaccinated women and followed up yearly. We assess type-specific prevalence, natural history and potential determinants of human papillomavirus (HPV) infection in these unvaccinated women. Cervical samples were collected yearly for at least four consecutive years. A Multiplex Type-Specific E7-Based polymerase chain reaction assay was used to detect 21 HPV types. HPV prevalence was 36.4% during 6 years. Most common HPV types were 16 (6.5%) and 31 (6.1%). Highest persistence were observed for HPV 35 (62.5%) and 52 (25%). New HPV acquisition rate was 5.6/1000 person-months of observation (PMO), highest for HPV 16 (1.1/1000 PMO). Type-specific clearance rates ranged between 2.9-5.5/100 PMO. HPV 16 and/or 18 infections were 41% (95% CI 4-63%) lower among women with 2-<3 years between marriage and first cervical sample collection compared to those with <2 years. HPV prevalence and acquisition rates in young Indian women were lower than their Western counterparts. HPV 16 infections being most common shows the importance and potential impact of HPV vaccination in India. Women with 2-3 years exposure had reduced risk possibly due to higher infections clearance.

PubMed Disclaimer

Conflict of interest statement

The corresponding authors, on behalf of all authors, declares the following potential competing interests: Neerja Bhatla has received research funding through her institute from GlaxoSmithKline and Merck. Smita Joshi has received funds from GlaxoSmithKline through the Jehangir Clinical Development Center to do an HPV vaccine study. Partha Basu has received research funding from GlaxoSmithKline through Chittaranjan National Cancer Institute, India during his previous position at the institute. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The other authors declare no competing interests.

Figures

Fig 1
Fig 1. Kaplan-Meier curves of cumulative probability of HPV infection among women negative for a specific type on their first cervical cell sample collection.
Fig 2
Fig 2. Kaplan-Meier curves of the proportion women who had type-specific HPV clearance.
Fig 3
Fig 3. Cervical cancer incidence reported by population-based cancer registries at the Indian study sites and rank of cervical cancer by incidence among all cancers in females (Data source: National Cancer Registry Programme, India).
See this image and copyright information in PMC

References

    1. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer. 2009;4:8 10.1186/1750-9378-4-8 - DOI - PMC - PubMed
    1. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24(Suppl 1):S1–15. 10.1016/j.vaccine.2005.09.054 - DOI - PubMed
    1. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992; 327(18):1272–8. 10.1056/NEJM199210293271804 - DOI - PubMed
    1. Maucort-Boulch D, Franceschi S, Plummer M; IARC HPV Prevalence Surveys Study Group. International correlation between human papillomavirus prevalence and cervical cancer incidence. Cancer Epidemiol Biomarkers Prev. 2008; 17(3):717–20. 10.1158/1055-9965.EPI-07-2691 - DOI - PubMed
    1. Sharma M, Bruni L, Diaz M, Castellsagué X, de Sanjosé S, Bosch FX, et al. Using HPV prevalence to predict cervical cancer incidence. Int J Cancer. 2013; 132(8):1895–900. 10.1002/ijc.27835 - DOI - PubMed

Publication types

Substances